CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon  

作　　者：Kai-lin Xu Hai Cheng 

机构地区：[1]Blood Diseases Institute,Xuzhou Medical University,Xuzhou,China [2]Department of Hematology,The Affiliated Hospital of Xuzhou Medical University,Xuzhou,China

出　　处：《Blood Science》2019年第2期156-160,共5页血液科学（英文）

摘　　要：Chimeric antigen receptor(CAR)-T-cell therapy has achieved significant success in the treatment of hematologic malignancies.However,treatment-related toxicity and side effects remain the major drawbacks.As an important effector cell in innate immunity,natural killer(NK)cells exert strong antitumor functions and have better application prospects in the immunotherapy of hematologic malignancies.Compared with T cells,NK cells exhibit several advantages such as MHC-independent recognition.CAR-modified NK(CAR-NK)cells may exhibit a better ability of killing tumor cells.Herein,we review mainly preclinical data related to the development of CAR-NK cells in treating blood cancers.

关 键 词：HEMATOLOGY IMMUNOTHERAPY NK cells 

分 类 号：R73[医药卫生—肿瘤]